Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2018 and Provide Clinical Development Update
Analysts and investors may participate in the conference call by utilizing the conference ID: 7830929 and dialing the following numbers:
- 800-458-4121 or 929-477-0324 for callers in
the United States - 0800 279 7204 or 44 (0)330 336 9411 for callers in the
United Kingdom - 0800 101 1732 or 49 (0)69 2222 2018 for calls in
Germany
Those interested in listening to the conference call live via the internet may do so by visiting the “Investors” page of Verona Pharma’s website at www.veronapharama.com and clicking on the “Events and presentations” link.
A webcast replay of the conference call (audio) will be available for 30 days on the “Investors” page of Verona Pharma’s website at www.veronapharma.com.
About
For further information, please contact:
Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer | info@veronapharma.com |
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) |
Tel: +44 (0) 20 7710 7600 |
Stewart Wallace / Jonathan Senior / Ben Maddison | |
FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 |
Simon Conway / Natalie Garland-Collins | veronapharma@fticonsulting.com |
ICR, Inc. (US Media and Investor enquiries) | |
James Heins | Tel: +1 203-682-8251 James.Heins@icrinc.com |
Stephanie Carrington | Tel. +1 646-277-1282 Stephanie.Carrington@icrinc.com |
Source: Verona Pharma plc